Author/Editor		Matičič, Mojca; Poljak, Mario; Tomažič, Janez; Vidmar, Ludvik; Kramar, Barbara; Skalerič, Uroš
Title		Detection of anti HIV-1/2 antibodies in saliva of HIV-seropositive persons in Slovenia
Translated title		Prisotnost protiteles proti HIV-1/2 v slini oseb, okuženih s HIV v Sloveniji
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 67, št. Suppl 2
Publication year		1998
Volume		str. II-83-6
Language		eng
Abstract		Background. To evaluate the sensitivity and specificitity of saliva-baed anti HIV antibody testing in the Slovenian population due to heterogeneity of HIV. Patients and methods. Serum and saliva samples from 35 persons previously determined as HIV-1 seropositive, and 50 persons of unknown HIV status with no risk factors for HIV infection were evaluated in a prospective, blinded fashion for anti HIV-1/2 antibodies. The clinical classificantion of HIV infection, serum HIV-1 RNA viral load and antiretroviral drug use were wel documented in all HIV-seropositive persons. Saliva was gathered with the Omni-Sal collection device designed to concentrate crevicular fluid rich saliva, and analysed for the presence of anti HIV-1/2 antibodies using the commercial enzyme immuno assay Wellocozyme HIV 1+2 GACELISA, and confirmatory Western blot test. Independently, serum samples were analysed for anti HIV-1/2 antibodies using two different commercial screening enzyme immuno assays (Wellcozyme HIV 1+2, Enzygnost Anti-HIV 1+2), and three different confirmatory Western blot tests. Results. All 35 persons previously determined as HIV-1 seropositive, expressing most various stages of HIV disease with a wide range of serum HIV-1 RNA load, and different variations in antiretroviral therapy, had detectable anti HIV-1 antibodies in saliva by both screening and confirmatory test. None of the 50 controls were positive by testing of serum or saliva specimens for the presence of anti HIV-1/2 antibodies. According to our study both the sensitivity and specificity of Wellcozyme HIV 1+2 Gacelisa were 100%. Conclusions. Our study confirmed that testing of saliva appears to be a simple, safe, sensitive and specific method for detecting anti HIV antibodies, used mostly for surveillance purposes.
Summary		Izhodišča. Zaradi virusne heterogenosti smo želeli na slovenski populaciji oceniti senzitivnost in specifičnost standardnih testnih metod za določanje protiteles proti HIV-1/2 v slini. Bolniki in metode. Študija je bila namenjena pregledu, slepa. Slino in serum 35 HIV-1 seropozitivnih oseb, ki so vse pregledane na Kliniki za infekcijske bolezni Kliničnega centra v Ljubljani, ter 50 naključno izbranih oseb, ki so bile zdravljene v isti ustanovi zaradi drugih bolezni, za katere pa nismo vedeli, če so okuženi s HIV in niso navajali nobenega dejavnika tveganja za okužbo s HIV, smo testirali glede prisotnosti protiteles proti HIV-1/2. HIV-1 seropozitivne osebe so se med seboj razlikovale stopnje bolezni, imunskega stanja, količine HIV-1 RNA v serumu in glede prejemanja antiretrovirusnih zdravil. Vzorec sline smo odvzeli s posebnim pripomočkom OMni-Sal, ki je prirejen za zbiranje sline, obogatene z gingivalno tekočino. S standardnim encimsko imunskim testom Wellcozyme HIV -+2 GACELISA smo vzorce sline testirali na prisotnost protiteles proti HIV-1/2 in pozitivne rezultate potrdili še z Western blot testom. Povsem ločeno smo testirali serum na prisotnost proti HIV-1/2 z dvema različnima standardnima encimsko imunskima presejalnima testoma (Wecozyme HIV 1+2 in Enzygnost Anti-HIV 1+2) ter pozitivne rezultate potrdili s tremi različnimi potrditvenimi Western blot testi. Rezultati. Vseh 35 HIV-1 seropozitivnih oseb je imelo v slini prisotna protitelesa proti HIV-1, kar smo prikazali tako s presejalnim kot tudi s potrditvenim testom. Nihče v kontrolni skupini ni imel prisotnost protiteles proti HIV-1/2, niti v serumu niti v slini. Senzitivnost in specifičnost Wellcozyme HIV 1+2 GACELISA testa za ugotavljanje protiteles proti HIV-1/2 v slini je bila 100%.(Izvleček prekinjen pri 2000 znakih.)
Descriptors		HIV SEROPOSITIVITY HIV INFECTIONS HIV ANTIBODIES SALIVA